Investor Relations

Press Releases

 
Press Releases
  Date Title View
Jan 6, 2016
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2016 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Roger Jeffs, Ph.D., President and Co-Chief Executive Officer, of United Therapeutics will provide an overview and update on the company's business at the 34th Annual J.P. Morgan Healthcare Conference ...
Oct 27, 2015
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2015 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2015. "We are pleased with our third quarter 2015 results as total revenues reached $386 million and each of our pulmonary arterial h...
Oct 21, 2015
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2015 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its third quarter 2015 financial results before market open on Tuesday, October 27, 2015. United Therapeutics will host a half-hour teleconference on Tuesday, October 27, 2015,...
Oct 15, 2015
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2015 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that its Board of Directors authorized the repurchase of up to an additional $500 million of the company's common stock.  This program will become effective on January 1, 2016, and will remain open for up...
Sep 30, 2015
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2015 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has entered into a Settlement Agreement with Sandoz Inc. ("Sandoz") relating to ongoing litigation concerning certain patents relating to United Therapeutics' product, Remodulin® (treprostin...
Aug 19, 2015
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2015 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PPRV) to a subsidiary of AbbVie Inc. (NYSE: ABBV). United Therapeutics received the PPRV when UnituxinT...
Aug 17, 2015
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 17, 2015 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin™ (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previo...
Aug 6, 2015
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 6, 2015 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Co-Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 2015 Wedbush PacGrow Healthcare Conferenc...
Jul 28, 2015
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2015. "Orenitram® sales grew nearly 300% as compared to the second quarter of 2014 when the product was first launched," said Roger ...
Jul 22, 2015
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 22, 2015 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its second quarter 2015 financial results before market open on Tuesday, July 28, 2015. United Therapeutics will host a half-hour teleconference on Tuesday, July 28, 2015, at 9...
1
... NextLast
= add release to Briefcase